from Wiktionary, Creative Commons Attribution/Share-Alike License.

  • noun A medication used in the treatment of Gaucher's disease, a recombinant DNA-produced analogue of human β-glucocerebrosidase.


Sorry, no etymologies found.


Help support Wordnik (and make this page ad-free) by adopting the word imiglucerase.


  • Patients enrolled in the trial were switched from imiglucerase doses ranging from around 10-60 U/kg every other week to an equivalent dose using the same number of units of taliglucerase alfa.

  • The data supports the efficacy and safety data package showing that patients can be switched from imiglucerase Cerezyme® to taliglucerase alfa.

  • VPRIV is for patients who are treatment naive as well as patients who have been treated with imiglucerase.

    Medlogs - Recent stories

  • The results suggest significant antigenic differences between velaglucerase alfa and imiglucerase, with only 1% seroconversion rates against velaglucerase alfa.

    RedOrbit News - Technology

  • (HGT-GCB-058) implemented to provide VPRIV to patients affected by the continuing shortage of imiglucerase.

    Medlogs - Recent stories

  • "Results from the Phase III study provide important information regarding the safety and sustained efficacy of VPRIV for patients with Type 1 Gaucher disease who were previously on imiglucerase and should help inform treatment decisions during and after the imiglucerase supply shortage," said Dr. Gregory Grabowski, Director of the Division of Human Genetics,

    Medlogs - Recent stories

  • Additionally, Shire reported important findings from a study that compared patient antibody response to velaglucerase alfa and imiglucerase.

    RedOrbit News - Technology

  • Cerezyme® (imiglucerase for injection) and Fabrazyme® (agalsidase beta) due to product supply constraints in 2010.

    American Chronicle

  • Genzyme expects that shipments of Cerezyme (imiglucerase for injection) and Fabrazyme

    Reliable Plant Homepage

  • The European regulator has also been told by Genzyme Corp that supply shortages for the firm's Gaucher disease drug Cerezyme (imiglucerase) and Fabry disease drug Fabrazyme (agalsidase beta) are continuing, following the well-documented problems at its manufacturing facility in the USA.

    PharmaTimes World News


Log in or sign up to get involved in the conversation. It's quick and easy.